Overview

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Status:
RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms
Phase:
PHASE4
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
Eli Lilly and Company